Below is the Privacy Policy that governs the website, under the ownership of PHARMA MAR.
Please take a few minutes to read our Privacy Policy. With it we want to explain to you in a simple, clear and transparent way how we treat and protect your personal information and your rights. Your security and that of your personal data are fundamental to us and we take its adequate protection very seriously.
CONTROLLER
Social Denomination: PHARMA MAR, SA
Registered Office: Avda. De los Reyes, 1, Pol. Ind. La Mina, 28770 - Colmenar Viejo (Madrid), Spain
CIF / NIF: A -78267176,
Telephone: (+34 ) 918466000
E - mail: pharmamar@pharmamar.com.
Contact with the Data Protection Officer: dpo@pharmamar.com.
WHAT IS YOUR DATA USED FOR?
On this page, your data can be collected through different sections, in relation to which we provide the following information:
|
Contact Form |
|
|
Purpose |
Provide a means for you to contact us and answer your requests for information. |
|
Legitimation |
Consent of the interested party. |
|
Conservation |
Your data will be kept until the resolution of your request if it has not generated a new processing and, in any case, as long as the possible legal actions derived from the purpose and processing do not prescribe |
RECIPIENTS
PHARMA MAR guarantees in any case the exercise of your rights. You have the right to withdraw the consent given at any time. Likewise, you may exercise your right of access, rectification, deletion, limitation, opposition to its processing, or portability.
INTERNATIONAL TRANSFERS
No international data transfers are made (outside the European Economic Area).
RIGHTS
Access: The interested party has the right to be informed if their personal data is being processed or not and, in case the processing is confirmed, to be provided with the processing information.
Reasons to exercise the right:
Rectification: The interested party has the right to have their data rectified when they are inaccurate or incomplete.
Reasons to exercise the right:
Erasure The interested party has the right to have their data deleted.
Reasons to exercise the right:
Opposition: The interested party has the right to object to the processing of their data for reasons related to their particular situation.
Reasons to exercise the right:
Restriction of processing: The interested party will have the right to have PHARMA MAR mark their data in order to restriction of processing.
Reasons to exercise the right:
Portability: The interested party has the right to have PHARMA MAR transmit their data to another RESPONSIBLE or to the same interested party, through a structured format of habitual use and mechanical reading.
Reasons to exercise the right:
Automated decision-making The interested party has the right not to be the subject of profiling whose purpose is to make individual decisions based on AUTOMATED data processing.
Reasons to exercise the right:
The interested party can exercise their rights by sending an express request, accompanied by a copy of their ID or other document proving their identity, through the following means:
E-Mail: pharmamar@pharmamar.com
Post mail: dpo@pharmamar.com
All the data marked with an asterisk are mandatory, since they are necessary for the correct management of your request. In the event that all data is not provided, PHARMA MAR does not guarantee that it can fulfill the purpose of the processing.
Likewise, if you consider that the processing of personal data does not comply with current regulations, we inform you that you have the right to file a claim with the Control Authority (www.aepd.es).
SECURITY
PHARMA MAR has adopted all the necessary technical and organizational measures to guarantee the security and integrity of the personal data provided by the user, as well as to prevent its loss, alteration and / or access by unauthorized third parties.
MODIFICATION
PHARMA MAR reserves the right to modify this policy to adapt it to future legislative, doctrinal or jurisprudential developments that may be applicable or for technical, operational, commercial, corporate and business reasons, previously and reasonably informing you of the changes that occur when it may be possible. In any case, it is recommended that, every time you access this platform, you read this policy in detail since any modification will be published through it.
Yondelis Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis#product-information-section
Yondelis (trabectedin) 0.25mg/ 1mg powder for concentrate for solution for infusion. SmPC Yondelis, July 2021. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. YON0723-1911 Date of revision of the promotional material: August 2023
If you wish to inform of an adverse event, please click here